Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025
What’s new today (Nov. 12) Canaccord bumps target to $107. Before the open, Canaccord Genuity’s Edward Nash inched his VKTX target up by $1 to $107 and kept a Buy rating, framing Viking as a high‑quality obesity asset. The update follows Canaccord’s October initiation and comes as investors digest Stifel conference commentary and the latest clinical posters. StreetInsider.com+1 Stock check. VKTX traded around the low‑$40s today as conference headlines and sell‑side notes hit the tape. (See the live chart above; for a public quote page, Reuters lists VKTX real‑time pricing and ranges.) Reuters Fund‑flow tidbits. 13F‑driven headlines this morning highlighted